MapLight Therapeutics reported Q4 and full year 2025 financial results with net loss of $79.5 million and $161.2 million respectively, cash position of $453.1 million funding through 2027, and provided pipeline updates including Phase 2 topline results expected in Q3 2026 for ML-007C-MA in schizophrenia and ML-004 in ASD.
Key takeaways
Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia to reach target enrollment n=300 in April 2026, topline Q3 2026
Phase 2 IRIS trial of ML-004 for ASD completed enrollment, topline Q3 2026
FDA Fast Track for ML-007C-MA in Alzheimer’s disease psychosis, Phase 2 VISTA topline 2H 2027